Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Rasool, Suhail ^a,b   Albay, Ricardo ^a   Martinez Coria, Hilda ^c   Breydo, Leonid ^a   Wu, Jessica ^a   Milton, Saskia ^a   Misra, Sunit ^a   Tran, Andy ^a   Pensalfini, Anna ^a   Laferla, Frank ^c   Kayed, Rakez ^d,e   Glabe, Charles G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3A PEPTIDE OLIGOMER; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ASTROCYTE; BEHAVIOR; BRAIN HEMORRHAGE; CELL ACTIVATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; MALE; MEMORY; MICROGLIA; NONHUMAN; RABBIT; TRANSGENIC MOUSE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ANTIGENS; BIOMIMETIC MATERIALS; COGNITION; HEMORRHAGE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; PROTEIN MULTIMERIZATION; VACCINATION;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84864497129     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-37     Document Type: Article

References (49)

1. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol (Berl) 1991 82 4 239 259 10.1007/BF00308809
2. Alzheimer's disease: the amyloid cascade hypothesis. Hardy JA, Higgins GA, Science 1992 256 5054 184 185 10.1126/science.1566067 1566067
3. Amyloid beta-protein and the genetics of Alzheimer's disease. Selkoe DJ, J Biol Chem 1996 271 31 18295 18298 8756120 (Pubitemid 26322675)
4. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Golde TE, Dickson D, Hutton M, Curr Alzheimer Res 2006 3 5 421 430 10.2174/156720506779025189 17168641 (Pubitemid 46066421)
5. A specific amyloid-beta protein assembly in the brain impairs memory. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. Nature 2006 440 7082 352 357 10.1038/nature04533 16541076
6. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. J Neurosci 2000 20 11 4050 4058 10818140 (Pubitemid 30365675)
7. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Nature 2002 416 6880 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
8. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Am J Pathol 1999 155 3 853 862 10.1016/S0002-9440(10)65184-X 10487842 (Pubitemid 29426831)
9. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ, Biochem Soc Trans 2002 30 4 552 557 12196135 (Pubitemid 35001597)
10. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Nature 1999 400 6740 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
11. Amyloid-beta immunisation for Alzheimer's disease. Wisniewski T, Konietzko U, Lancet Neurol 2008 7 9 805 811 10.1016/S1474-4422(08)70170-4 18667360
12. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's Disease. Zhou J, Fonseca MI, Kayed R, Webster SD, Hernandez I, Yazan O, et al. J Neuroinflammation 2005 2 1 28 10.1186/1742-2094-2-28 16332263 (Pubitemid 41819440)
13. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Mol Neurodegener 2007 2 18 18 17897471
14. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, et al. PLoS One 2010 5 10 13391 10.1371/journal.pone.0013391 20967130
15. Immune function of microglia. Aloisi F, Glia 2001 36 2 165 179 10.1002/glia.1106 11596125 (Pubitemid 33055905)
16. Microglia and Alzheimer's disease pathogenesis. Streit WJ, J Neurosci Res 2004 77 1 1 8 10.1002/jnr.20093 15197750 (Pubitemid 38850050)
17. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. Wilcock DM, Colton CA, CNS Neurol Disord Drug Targets 2009 8 50 64 10.2174/187152709787601858 19275636
18. Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. Fisher M, Vasilevko V, Passos GF, Ventura C, Quiring D, Cribbs DH, Stroke 2011 42 3300 3303 10.1161/STROKEAHA.111.626655 21903962
19. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 5580 353 356 10.1126/science.1072994 12130773 (Pubitemid 34790756)
20. Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Schenk D, Nat Rev Neurosci 2002 3 10 824 828 10.1038/nrn938 12360327 (Pubitemid 135706694)
21. Concurrent muscarinic and beta-adrenergic blockade in rats impairs place-learning in a water maze and retention of inhibitory avoidance. Decker MW, Gill TM, McGaugh JL, Brain Res 1990 513 1 81 85 10.1016/0006-8993(90)91091-T 2161697 (Pubitemid 20144275)
22. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, et al. Exp Neurol 2002 173 2 183 195 10.1006/exnr.2001. 7754 11822882 (Pubitemid 34151370)
23. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C, Neurobiol Dis 2001 8 5 792 806 10.1006/nbdi.2001.0431 11592849 (Pubitemid 33055596)
24. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG, J Neurosci 2001 21 2 372 381 11160418 (Pubitemid 32107428)
25. Plaque biogenesis in brain aging and Alzheimer's disease. II. Progressive transformation and developmental sequence of dystrophic neurites. Su JH, Cummings BJ, Cotman CW, Acta Neuropathol 1998 96 5 463 471 10.1007/s004010050920 9829809 (Pubitemid 28474753)
26. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Nat Med 2000 6 8 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
27. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. J Neurosci 2002 22 18 7873 7878 12223540 (Pubitemid 35379092)
28. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. Nature 2000 408 6815 982 985 10.1038/35050116 11140686 (Pubitemid 32101645)
29. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. [Comment In: Nature. 2000 Dec 21-28;408(6815):915-6 UI: 21020929]. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Nature 2000 408 6815 979 982 10.1038/35050110 11140685 (Pubitemid 32101644)
30. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. J Neurosci 2002 22 15 6331 6335 12151510 (Pubitemid 35386387)
31. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Neurology 2003 61 1 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155 (Pubitemid 36818745)
32. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Neurology 2005 64 1 129 131 10.1212/01.WNL.0000148590.39911.DF 15642916 (Pubitemid 40082949)
33. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO, Nat Med 2003 9 4 448 452 10.1038/nm840 12640446 (Pubitemid 36460079)
34. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F, Brain Pathol 2004 14 1 11 20 14997933 (Pubitemid 38200585)
35. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Neurology 2005 64 9 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
36. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Am J Pathol 2006 169 3 1048 1063 10.2353/ajpath.2006.060269 16936277 (Pubitemid 44411966)
37. Abeta species removal after abeta42 immunization. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. J Neuropathol Exp Neurol 2006 65 11 1040 1048 10.1097/01.jnen.0000240466.10758.ce 17086100 (Pubitemid 44684661)
38. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, et al. Proc Natl Acad Sci U S A 2009 106 29 12145 12150 10.1073/pnas.0904866106 19581601
39. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Fillit H, Hess G, Hill J, Bonnet P, Toso C, Neurology 2009 73 3 180 185 10.1212/WNL.0b013e3181ae7aaf 19620605
40. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Science 2003 300 5618 486 489 10.1126/science.1079469 12702875 (Pubitemid 36444329)
41. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R, Science 2005 307 5707 262 265 10.1126/science.1105850 15653506 (Pubitemid 40116242)
42. Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. Kodali R, Williams AD, Chemuru S, Wetzel R, J Mol Biol 2010 401 3 503 517 10.1016/j.jmb.2010.06.023 20600131
43. Structural classification of toxic amyloid oligomers. Glabe CG, J Biol Chem 2008 283 44 29639 29643 10.1074/jbc.R800016200 18723507
44. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. Necula M, Kayed R, Milton S, Glabe CG, J Biol Chem 2007 282 14 10311 10324 10.1074/jbc.M608207200 17284452 (Pubitemid 47093410)
45. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, et al. Mol Neurodegener 5 57
46. Conformation-dependent anti-amyloid oligomer antibodies. Kayed R, Glabe CG, Methods Enzymol 2006 413 326 344 17046404 (Pubitemid 44528698)
47. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM, Neuron 2005 45 5 675 688 10.1016/j.neuron.2005.01.040 15748844 (Pubitemid 40320703)
48. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, et al. Nature 2000 408 6815 975 979 10.1038/35050103 11140684 (Pubitemid 32101643)
49. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Nat Neurosci 2002 5 5 452 457 11941374 (Pubitemid 34454251)